Newsroom
Sorted by: Latest
-
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. Preliminary Unaudited Financial Results For the fourth quarter ended December 31, 2025, as compared to the same period of 2024, Veracyte expects to report: Total revenue of between $138 million and $140 million, an increase of between 16% and 18% Testing revenue of...
-
Joint Statement Regarding Resolution of Litigation Between Aristocrat and Light & Wonder
LAS VEGAS--(BUSINESS WIRE)--Aristocrat Leisure Limited (ASX:ALL) and Light & Wonder (ASX:LNW) have agreed to settle their pending litigation in Australia and the United States which Aristocrat brought following the launch of Light & Wonder’s Dragon Train game, which Aristocrat contends was developed using Aristocrat’s trade secrets and copyright works. Aristocrat later made similar claims against Light & Wonder’s Jewel of the Dragon game. While the specific terms of the settlement r...
-
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis anticipates 2026 will be a significant year of clinical, regulatory and commercial progress as the company grows its current cabozantinib business, works toward building a potential second commercial franchise with zanzalintinib and moves its earlier...
-
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2025, as well as provided 2026 product revenue guidance and select milestones for 2026. “2025 was a remarkable year for Cerus, as patient access to INTERCEPT treated blood components increased meaningfully around the world,” said William “Obi” Greenman, Cerus’ president and chief executive officer. “During 2025, based on the number of kits sold, we...
-
Vibe Retail POS Sets the Standard for Retail-Focused Point-of-Sale Technology
BROOKLYN, N.Y.--(BUSINESS WIRE)--Vibe POS is gaining recognition for its retail-only point-of-sale platform as retailers seek purpose-built alternatives to multi-vertical POS systems....
-
Direct Source Highlights the Hottest Retail Technology Innovations at NRF Big Show 2026
MINNEAPOLIS & NEW YORK--(BUSINESS WIRE)--As we enter 2026, in-store shopping continues to evolve, embracing a more experiential approach. Trends like shoppertainment, phygital integrations, AI-driven customization and frictionless payments are emerging as consumers demand a more immersive, brand-led experience. Direct Source will showcase a range of these in-store technologies at NRF: Retail’s Big Show, January 11–13 in New York City, booth #6039. Attendees can explore AI-powered self-service a...
-
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen (Nasdaq: BIIB) as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced accelerated timelines for the completion of enrollment and a Phase 3 data readout from the EMPEROR...
-
Debiopharm Deploys Genialis Software to Advance AI-Based Biomarker Discovery
BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--Genialis expands its collaboration with Debiopharm, deploying Expressions to support standardized biomarker discovery and multiomics analytics....
-
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era
NEW YORK--(BUSINESS WIRE)--Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insig...
-
Sensormatic Solutions Introduces EAS-based, Category-level Shrink Intelligence at NRF Big Show
NEUHAUSEN, Switzerland--(BUSINESS WIRE)--Sensormatic Solutions, the leading global retail solutions portfolio of Johnson Controls (NYSE: JCI), is offering retailers a new way to implement a data-driven approach to LP and organized retail crime (ORC) prevention using trusted acousto-magnetic (AM) technologies. Its Category-Level Shrink Insights ecosystem is designed to turn existing electronic article surveillance (EAS) infrastructure into an intelligent LP solution, driving operational improvem...